OR WAIT null SECS
June 21, 2024
Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.
June 20, 2024
The acquisition of the 87,000 square-foot Camden, MD plant provides the CDMO with the ability to offer clinical and commercial non-viral aseptic fill-finish services on four fill lines.
June 19, 2024
Deal will target neurological diseases, featuring an initial payment of $42 million for Ascidian and up to $1.8 billion in milestone payments/royalties.
June 06, 2024
An analysis of the general medicine portion of the pharmacy market amid ensuing challenges.
May 31, 2024
Financial commitment will go toward expanding the CDMO’s integrated antibody-drug conjugate services.
May 24, 2024
The deal grows it pipeline, powered by panCAR programs in autoimmune disease and oncology.
With the acquisition, Merck’s US and Canada life science business aims to further increase its viral vector manufacturing capabilities.
May 23, 2024
The deal features felzartamab, an investigational anti-CD38 monoclonal antibody, whose clinical outcomes have shown potential to tackle various immune-mediated diseases.
May 21, 2024
The agreement is expected to focus on cell manufacturing processes, with potential for sharing tech with academia, startups.
May 20, 2024
The facility, company says, will be its first that covers end-to-end ADC production.